PET/CT with Tracers for Breast Cancer

Recruiting in Palo Alto (17 mi)

Overseen byDavid M Schuster, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Emory University

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial uses special substances that emit tiny amounts of radiation to create detailed images of the inside of the body. It targets patients with a specific type of breast cancer that may have spread. The substances help highlight cancer spots during scans, aiding doctors in better detecting and understanding the spread of cancer.

Research Team

David M Schuster, MD

Principal Investigator

Emory University Hospital/Winship Cancer Institute

Eligibility Criteria

This trial is for patients with invasive lobular breast cancer that may have spread, who haven't started treatment yet. They should be open to biopsies if needed. Pregnant women or those able to conceive without being postmenopausal for at least a year (if over 55) can't join.

Inclusion Criteria

My scans or symptoms suggest my cancer may have spread more than previously thought.

I have invasive lobular carcinoma (ILC) and haven't received any treatment.

I am willing to have a biopsy if my doctor thinks it's necessary.

Exclusion Criteria

I am a woman who can still have children and have not been through menopause for 12 months.

Pregnancy

Treatment Details

Interventions

Computed Tomography (Procedure)
Fluciclovine F18 (Radiotracer)
Gallium Ga 68 Gozetotide (Radiotracer)
Positron Emission Tomography (Procedure)

Trial OverviewThe study tests how well two PET/CT imaging scans using fluciclovine and PSMA radiotracers work in classifying and staging invasive lobular breast cancer that might have metastasized.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Diagnostic (Ga PSMA, fluciclovine F18, PET/CT)Experimental Treatment4 Interventions

Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan over 30 minutes. On a separate day, patients receive fluciclovine F18 IV and undergo a PET/CT scan over 30 minutes.